Picture of BioPorto A/S logo

BIOPOR BioPorto A/S News Story

dk flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapNeutral

REG - Malin Corp PLC - Directorate Change


RNS Number : 4800H
Malin Corporation PLC
25 March 2020

Malin Corporation plc


Directorate Change

Appointment of New Directors


Dublin-Ireland, 25 March 2020: Malin Corporation plc. (Euronext Growth Dublin:MLC) ("Malin", the "Company"), a company investing in highly innovative life sciences companies, today announces the appointment of Dr Kirsten Drejer and Luke Corning as Non-Executive Directors and Darragh Lyons, Chief Executive Officer, as Executive Director, effective from 24 March 2020.


Welcoming today's announcement, Chairman Liam Daniel said:


"On behalf of the Malin Board, I am delighted to welcome Dr Kirsten Drejer and Luke Corning as Non-Executive Directors, who bring highly relevant skills and experience to Malin. Recognising the importance of strong leadership at an executive level, we appointed Darragh Lyons to the role of CEO in September 2019, who also now joins the Board. I am confident that the new appointments will add quality and depth to Malin's healthcare focus and governance framework as we look forward to important and value enhancing milestones across our investee companies in 2020."


Dr Kirsten Drejer founded and served as CEO of Symphogen, a Danish private biopharmaceutical company, and has extensive board experience on both private and public companies across the life sciences sector, including Zealand Pharma, where she currently serves as vice-chairman of the board, Bioporto and Alligator Bioscience.

Luke Corning is head of the Credit and Special Situations group at Pentwater Capital Management LP ("Pentwater").  Pentwater holds a 26% economic interest in Malin through a number of counterparties, as announced in October 2019.   Over the course of his investment management career, Mr Corning has served on the boards of several private and public companies across a range of sectors.

Darragh Lyons was appointed CEO of Malin in September 2019 having previously held the positions of Chief Business and Financial Officer, and Chief Financial Officer of Malin.


Regulatory disclosures


Other than as set out in the Schedule hereto, there are no other matters required to be disclosed pursuant to Schedule Two, paragraph (g) of Chapter 5: Additional Rules for the Euronext Growth Market operated by Euronext Dublin as regards the appointments of Dr Kirsten Drejer or Messrs. Corning or Lyons.




About Malin Corporation plc

Malin (Euronext Growth Dublin:MLC) is a company investing in highly innovative life sciences companies. Its purpose is to create shareholder value through the application of long-term capital and operational and strategic expertise to a diverse range of global healthcare businesses. Malin has a focus on innovative businesses underpinned by exceptional science and works with its investee companies, providing strategic and financial support to enable them to reach their value potential. Malin is headquartered and domiciled in Ireland and listed on the Euronext Growth Dublin. For more information visit www.malinplc.com 


For further information, please contact:



Jessica Bergin, Investor Relations & External Reporting

Tel: +353 (0)1 901 5700



Davy Corporate Finance (Euronext Growth Adviser & Joint Broker)

Brian Garrahy / Daragh O'Reilly

Tel: +353 1 679 6363


Liberum (Joint Broker)

Bidhi Bhoma / Euan Brown

Tel: +44 (0) 20 3100 2000


Consilium Strategic Communications

Mary-Jane Elliott / Chris Welsh / Angela Gray

Tel: +44 (0)20 3709 5700



Powerscourt (Irish media enquiries)         

Jack Hickey

Tel: +353 83 448 8339                            























Regulatory Disclosures


Dr Kirsten Aarup Drejer (née Philipsen) (Age 64)


Current Directorships

Directorships within the past 5 years

Alligator Bioscience AB

Symphogen A/S

Zealand Pharma A/S

Danish Growth Fund (Vaekstfonden)

Bioporto Diagnostics A/S

Bionor Pharma AS

Bioneer A/S

Lyhne Life

Antag Therapeutics ApS

ResoTher Pharma ApS


Luke David Corning (Age 38)


Current Directorships

Directorships within the past 5 years

JW Aluminum Inc.

American Apparel Inc.

American Standard Energy Corp.


Luke Corning is an employee of Pentwater Capital Management LP, an organisation which holds a 26% economic interest in Malin through a number of counterparties.


Luke Corning was appointed to the board of American Apparel, Inc. ("American Apparel") between 5 February 2016 and 31 March 2017. American Apparel voluntarily filed for Chapter 11 bankruptcy protection on November 14, 2016. On November 14, 2016, Gildan Activewear Inc. ("Gildan") entered into an asset purchase agreement with American Apparel that served as the initial bid in a Bankruptcy Court-supervised auction. Following approval by the Bankruptcy Court, on February 8, 2017, Gildan announced that it had completed the acquisition of the American Apparel brand and certain assets from American Apparel.


Darragh Fergal Lyons (Age 39)


Current Directorships

Directorships within the past 5 years

Malin Life Sciences Holdings Limited

Malin Corporation plc

Malin Life Sciences International Limited

Harbour Square Corporate Secretaries Limited

An2H Discovery Limited

3D4 Medical Limited

Altan Pharma Limited

Brandon Point Industries Unlimited Company

Nidus Laboratories Ireland Limited

Brandon Point Management Services Unlimited Company

Hatchill Limited

Malin Life Sciences (UK) Limited

NeuVT Limited

Emba Medical Limited

Emba Neuro Limited

Neurobiometrix Limited

Serenus Biotherapeutics Limited

Brandon Point Enterprises 1 Limited

Malin Life Sciences (US) Inc.


Darragh Lyons holds 54,176 Ordinary Shares and 65,250 unvested Restricted Stock Units in Malin. He has a 1% economic interest in Brandon Point Industries, an Irish life sciences holding company, which holds 3,279,299 Founder A Ordinary Shares in Malin. The Founder A Ordinary Shares convert to Ordinary Shares upon the achievement by the Company of performance thresholds or upon a change of control.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Recent news on BioPorto A/S

See all news